Global Cancer (Tumor) Profiling Market Insights, Forecast to 2025

2 Global Cancer (Tumor) Profiling Quarterly Market Size Analysis

• 2.1 Cancer (Tumor) Profiling Business Impact Assessment - COVID-19
  • 2.1.1 Global Cancer (Tumor) Profiling Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Cancer (Tumor) Profiling Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Cancer (Tumor) Profiling Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Cancer (Tumor) Profiling Headquarters and Area Served
• 3.3 Date of Key Players Enter into Cancer (Tumor) Profiling Market
• 3.4 Key Players Cancer (Tumor) Profiling Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Cancer (Tumor) Profiling Segments, By Type

• 4.1 Introduction
  • 1.4.1 Immunoassay
  • 1.4.2 Hybridization
  • 1.4.3 NGS
  • 1.4.4 Mass Spectrometry
• 4.2 By Type, Global Cancer (Tumor) Profiling Market Size, 2019-2021

5 Impact of Covid-19 on Cancer (Tumor) Profiling Segments, By Application

• 5.1 Overview
  • 5.5.1 Clinical
  • 5.5.2 Research
• 5.2 By Application, Global Cancer (Tumor) Profiling Market Size, 2019-2021
  • 5.2.1 By Application, Global Cancer (Tumor) Profiling Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Illumina
  • 7.1.1 Illumina Business Overview
  • 7.1.2 Illumina Cancer (Tumor) Profiling Quarterly Revenue, 2020
  • 7.1.3 Illumina Cancer (Tumor) Profiling Product Introduction
  • 7.1.4 Illumina Response to COVID-19 and Related Developments
• 7.2 Qiagen
  • 7.2.1 Qiagen Business Overview
  • 7.2.2 Qiagen Cancer (Tumor) Profiling Quarterly Revenue, 2020
  • 7.2.3 Qiagen Cancer (Tumor) Profiling Product Introduction
  • 7.2.4 Qiagen Response to COVID-19 and Related Developments
• 7.3 Neogenomics Laboratories
  • 7.3.1 Neogenomics Laboratories Business Overview
  • 7.3.2 Neogenomics Laboratories Cancer (Tumor) Profiling Quarterly Revenue, 2020
  • 7.3.3 Neogenomics Laboratories Cancer (Tumor) Profiling Product Introduction
  • 7.3.4 Neogenomics Laboratories Response to COVID-19 and Related Developments
• 7.4 HTG Molecular Diagnostics
  • 7.4.1 HTG Molecular Diagnostics Business Overview
  • 7.4.2 HTG Molecular Diagnostics Cancer (Tumor) Profiling Quarterly Revenue, 2020
  • 7.4.3 HTG Molecular Diagnostics Cancer (Tumor) Profiling Product Introduction
  • 7.4.4 HTG Molecular Diagnostics Response to COVID-19 and Related Developments
• 7.5 Genomic Health
  • 7.5.1 Genomic Health Business Overview
  • 7.5.2 Genomic Health Cancer (Tumor) Profiling Quarterly Revenue, 2020
  • 7.5.3 Genomic Health Cancer (Tumor) Profiling Product Introduction
  • 7.5.4 Genomic Health Response to COVID-19 and Related Developments
• 7.6 Caris Life Sciences
  • 7.6.1 Caris Life Sciences Business Overview
  • 7.6.2 Caris Life Sciences Cancer (Tumor) Profiling Quarterly Revenue, 2020
  • 7.6.3 Caris Life Sciences Cancer (Tumor) Profiling Product Introduction
  • 7.6.4 Caris Life Sciences Response to COVID-19 and Related Developments
• 7.7 Helomics Corporation
  • 7.7.1 Helomics Corporation Business Overview
  • 7.7.2 Helomics Corporation Cancer (Tumor) Profiling Quarterly Revenue, 2020
  • 7.7.3 Helomics Corporation Cancer (Tumor) Profiling Product Introduction
  • 7.7.4 Helomics Corporation Response to COVID-19 and Related Developments
• 7.8 Nanostring Technologies
  • 7.8.1 Nanostring Technologies Business Overview
  • 7.8.2 Nanostring Technologies Cancer (Tumor) Profiling Quarterly Revenue, 2020
  • 7.8.3 Nanostring Technologies Cancer (Tumor) Profiling Product Introduction
  • 7.8.4 Nanostring Technologies Response to COVID-19 and Related Developments
• 7.9 Oxford Gene Technology
  • 7.9.1 Oxford Gene Technology Business Overview
  • 7.9.2 Oxford Gene Technology Cancer (Tumor) Profiling Quarterly Revenue, 2020
  • 7.9.3 Oxford Gene Technology Cancer (Tumor) Profiling Product Introduction
  • 7.9.4 Oxford Gene Technology Response to COVID-19 and Related Developments
• 7.10 Ribomed Biotechnologies
  • 7.10.1 Ribomed Biotechnologies Business Overview
  • 7.10.2 Ribomed Biotechnologies Cancer (Tumor) Profiling Quarterly Revenue, 2020
  • 7.10.3 Ribomed Biotechnologies Cancer (Tumor) Profiling Product Introduction
  • 7.10.4 Ribomed Biotechnologies Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US